Is Wegovy Once a Month, Once a Week, or Something Else?

Step 1: understanding what 'monthly' actually means on Wegovy

The reason this question comes up so often is that people hear Wegovy described in four-week blocks and assume each block is a single injection. It isn't. You inject once a week, every week, for as long as treatment continues. What changes roughly every four weeks is the dose level, not the frequency.

Think of it as a ladder with monthly rungs. You begin at 0.25 mg for the first four weeks, a starting dose designed to let your body adjust rather than to drive significant weight loss straight away. If you tolerate it well, your prescriber moves you to 0.5 mg for the next four weeks, then 1.0 mg, then 1.7 mg, and finally to the 2.4 mg maintenance dose. Each step still involves four separate weekly injections. The once-a-week schedule never changes, even as the dose does.

In April 2026 the MHRA approved a 7.2 mg pen, a higher maintenance option for eligible adults with a BMI of 30 or above. This follows the same weekly injection pattern, titrated up from the standard starting point by a prescriber. You can read more about how the schedule is structured on the Wegovy overview page.

Step 2: what each weekly injection involves in practice

The pen itself is pre-filled and pre-set, there is no dial to turn or dose to draw up. You rotate injection sites between your abdomen, thigh and upper arm, clean the area, and press the pen against your skin until you hear a click. The whole process takes under a minute once you're used to it.

Timing matters: pick a day of the week you can stick to consistently. If you need to shift it by a day or two (for a holiday, say) the Patient Information Leaflet explains the minimum gap rules, and your prescriber can advise. The question of adjusting injection day is one that comes up regularly; there are specific guidance points worth reading before you change anything.

Storage is straightforward between injections. Wegovy pens are kept refrigerated at 2–8°C. If you're travelling, there is a limited window during which the pen can be kept at room temperature, the exact details are in the leaflet that comes with each pen, and your prescriber can confirm the window for your specific dose. The pen arrives by next-working-day DPD in plain, unbranded packaging, with a tracking notification on your phone the morning it's on its way.

Step 3: how weight loss tends to build across monthly milestones

Because Wegovy is titrated gradually, people often notice the clearest appetite changes once they reach higher dose levels, typically from around the 1.0 mg and 1.7 mg steps onward. That means the early monthly periods are largely about tolerability rather than maximum effect. Understanding this helps set realistic expectations for the first month on Wegovy and makes the second month's experience easier to interpret.

The STEP 1 clinical trial, published in the New England Journal of Medicine, found an average body-weight reduction of around 15% over 68 weeks at the 2.4 mg maintenance dose, alongside a reduced-calorie diet and increased activity. Results at the 7.2 mg dose in subsequent studies approached around 20.7% on average over 72 weeks. Individual responses vary; a prescriber reviews progress at regular intervals to assess whether continuing is appropriate.

For a broader picture of how outcomes develop over time, the third month of treatment is often when patients start to see a more consistent pattern. If you are thinking about costs alongside the schedule, the Wegovy sourcing and pricing page covers what to expect from legitimate private supply.

Who can follow this schedule, and who decides

Wegovy is licensed in the UK for adults with a BMI of 30 or above, or 27 to 29.9 with at least one weight-related health condition, such as high blood pressure, type 2 diabetes or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. BMI alone does not guarantee a prescription; the prescriber looks at your full health picture, including any medicines you already take and any contraindications.

The medicine is not licensed for anyone under 18, and it is not recommended during pregnancy, while breastfeeding, or when trying to conceive. The MHRA's guidance on GLP-1 medicines, summarised on the NHS semaglutide medicines page, is the clearest patient-level reference for contraindications and what to watch for once treatment starts. Your prescriber will also ask about any oral contraceptives you take, since semaglutide's interaction profile with other medicines forms part of the clinical review. Any decision to start, adjust or stop treatment sits with a qualified clinician, not an algorithm, and not this page.